Isabelle Mahé: Reduced-Dose Apixaban Lowers Bleeding Risk in CAT Without Losing Efficacy
Isabelle Mahé, Head of Internal Medicine at the Louis Mourier Hospital, APHP at Paris Cité University, shared a post on LinkedIn about several recent articles she and her colleagues co-authored, adding:
”In patients with CAT receiving extended treatment, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding․
4 clinical predictors were significantly associated with increased CRB risk:
- anaemia and/or
- thrombocytopenia,
- age ≥75, PE as the index event,
- male sex (The Lancet Haematology)․
The accumulation of bleeding risk predictors emerged as a major determinant of clinically relevant bleeding, with consistent patterns across dosing regimens. (The Lancet Haematology)․
In patients with bleeding risk predictors, a lower clinically relevant bleeding with reduced-dose apixaban was observed.
Those data reinforce the clinical relevance of the API-CAT findings, including for patients with non-modifiable bleeding risk factors․
Please read our reply just published in The Lancet Haematology!”
Title 1: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez
Read the Full Article on The New England Journal of Medicine․
Title 2: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology․
Title 3: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors’ reply
Authors: Isabelle Mahé, Céline Chapelle, Silvy Laporte
Read the Full Article on The Lancet Haematology․
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 23, 2026, 20:46Grace Choung: A Novel CFHR5 Copy Number Variant in Postpartum Atypical HUS
-
Jul 23, 2026, 20:10Mohammad Alzoubi: One Month of Dual Antithrombotic Therapy After PCI Was Non-Inferior to 12 Months
-
Jul 23, 2026, 20:08Ahmed Bennis: Calcitriol Replenishment May Mitigate Ischemic Risk in MASLD
-
Jul 23, 2026, 20:06Mitsuaki Sawano: Can Cardiovascular Risk Prediction Models Developed in One Population be Reliably Applied to Another?
-
Jul 23, 2026, 20:05Abdul Muqtadir Abbasi: Hemostasis Isn’t About Memorizing Factor Numbers – It’s About Recognizing Patterns
-
Jul 23, 2026, 19:40Maureen Macharia: How Apixaban Transformed Modern Anticoagulation
-
Jul 23, 2026, 19:30Jordan Agay: Why We Need to Track the Neurological Costs of Anemia
-
Jul 23, 2026, 19:25William Archibald: Key Takeaways on VTE Cost-Effectiveness and Cancer Associated Thrombosis from ISTH 2026
-
Jul 23, 2026, 19:17Diego López Santos: Donation after Donation, I Just Reached 100